Key result
Celecoxib demonstrated favorable cost-effectiveness profiles and lower direct medical costs compared with nonselective NSAIDs and other active treatments.
Why the study?
Does celecoxib reduce healthcare costs in patients with rheumatoid arthritis and osteoarthritis?
Systematic Review (n=24)
Yes
Does celecoxib reduce healthcare costs in patients with rheumatoid arthritis and osteoarthritis?
Celecoxib demonstrates a favorable cost-effectiveness profile and lower direct medical costs compared to nonselective NSAIDs in patients with osteoarthritis and rheumatoid arthritis.
Supports celecoxib prioritization to cut OA/RA costs; confirms economic advantage over nonselective NSAIDs in systematic review.
Osteoarthritis and rheumatoid arthritis are conditions that are associated with significant clinical burden, and impact on patients' functional status and quality of life. Medical costs related to treating these common and disabling conditions place an economic strain on healthcare systems. This systematic review was conducted to investigate the impact of celecoxib on healthcare costs for patients with rheumatoid arthritis and osteoarthritis. In total, 24 studies examined economic outcomes associated with celecoxib in patients with these conditions. Six of these studies evaluated economic outcomes in developing regions, including Mexico, Asia and Turkey. Across all geographies, most studies were cost-effectiveness analyses comparing celecoxib with nonselective NSAIDs alone or in combination with gastroprotective agents. Overall, based on local standards, economic models indicated favorable cost-effectiveness profiles for celecoxib compared with nonselective NSAIDs and other active-treatment options. Cost analyses indicated that the use of celecoxib resulted in lower direct medical costs.
No takes yet. Share an insight, caveat, or question.
Huelin et al. (2012) conducted a systematic review in Rheumatoid arthritis and osteoarthritis (n=24). Celecoxib vs. Nonselective NSAIDs alone or in combination with gastroprotective agents was evaluated on Healthcare costs and cost-effectiveness. Celecoxib demonstrated favorable cost-effectiveness profiles and lower direct medical costs compared with nonselective NSAIDs and other active treatments.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: